“Retirement Secret” Showed 995% Gain Last Time We Shared It

Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.

Find out why right here (and see what you can do to get in too with just a few dollars).

Arthur Levin Biography and Net Worth

Insider of Avidity Biosciences

Arthur Levin is a key opinion leader in the RNA therapeutics field. He serves as the CSO at Avidity Biosciences. Previously, he held Senior levels positions at mRiragen, Santaris Pharma, and Ionis Pharmaceuticals. He played key roles in developing numerous of oligonucleotides including the first approved antisense drugs and the first microRNA-targeted therapeutic in clinical trials. He has three decades of experience in drug development from discovery through drug registration. Dr. Levin has published over 60 scientific articles and several of the most cited reviews in the field. He is on the scientific advisory boards of multiple institutions. Art received a doctorate in toxicology from the University of Rochester.

What is Arthur A. Levin's net worth?: The estimated net worth of Arthur A. Levin is at least $353,398.90 as of April 19th, 2024. Dr. Levin owns 14,830 shares of Avidity Biosciences stock worth more than $353,399 as of April 26th. This net worth evaluation does not reflect any other investments that Dr. Levin may own. Learn More about Arthur A. Levin's net worth.
How do I contact Arthur A. Levin?: The corporate mailing address for Dr. Levin and other Avidity Biosciences executives is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. Avidity Biosciences can also be reached via phone at 858-401-7900 and via email at [email protected]. Learn More on Arthur A. Levin's contact information.
Has Arthur A. Levin been buying or selling shares of Avidity Biosciences?: During the last quarter, Arthur A. Levin has sold $656,300.00 of Avidity Biosciences stock. Most recently, Arthur A. Levin sold 5,000 shares of the business's stock in a transaction on Friday, April 19th. The shares were sold at an average price of $22.82, for a transaction totalling $114,100.00. Following the completion of the sale, the director now directly owns 14,830 shares of the company's stock, valued at $338,420.60. Learn More on Arthur A. Levin's trading history.
Are insiders buying or selling shares of Avidity Biosciences?: During the last year, insiders at the biotechnology company sold shares 10 times. They sold a total of 217,337 shares worth more than $4,805,041.71. The most recent insider tranaction occured on April, 19th when Director Arthur A Levin sold 5,000 shares worth more than $114,100.00. Insiders at Avidity Biosciences own 2.0% of the company. Learn More about insider trades at Avidity Biosciences.
Information on this page was last updated on 4/19/2024.

Arthur A. Levin Insider Trading History at Avidity Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/19/2024	Sell	5,000	$22.82	$114,100.00	14,830
4/3/2024	Sell	20,000	$27.11	$542,200.00	253,872
3/12/2024	Sell	27,641	$22.03	$608,931.23	14,830
1/22/2024	Sell	1,859	$10.13	$18,831.67	17,471
2/14/2023	Sell	10,000	$23.66	$236,600.00	19,330
1/12/2023	Sell	10,000	$22.00	$220,000.00	1,330
8/15/2022	Sell	62,498	$22.12	$1,382,455.76	1,330
8/12/2022	Sell	14,003	$22.00	$308,066.00	1,330
11/18/2021	Sell	25,000	$27.89	$697,250.00
6/25/2021	Sell	20,100	$28.12	$565,212.00	1,430
6/17/2021	Sell	200	$27.75	$5,550.00	1,530
6/14/2021	Sell	14,003	$25.92	$362,957.76
3/16/2021	Sell	4,600	$27.87	$128,202.00	2,625

Arthur A. Levin Buying and Selling Activity at Avidity Biosciences

Avidity Biosciences Company Overview

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Today's Range

Now: $23.83

$23.35

$24.96

50 Day Range

MA: $21.95

$13.98

$26.87

2 Week Range

Now: $23.83

$4.82

$27.66

Volume

1,243,328 shs

Average Volume

1,166,838 shs

Market Capitalization

$1.90 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.78